{"name":"Nobelpharma","slug":"nobelpharma","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Metabolic","slug":"metabolic","revenue":0,"percentOfTotal":0,"drugCount":5,"colorKey":"immunology","drugs":[{"name":"IKH-01","genericName":"IKH-01","slug":"ikh-01","indication":"Type 2 diabetes","status":"phase_3"},{"name":"NPC-09","genericName":"NPC-09","slug":"npc-09","indication":"Type 2 diabetes","status":"phase_3"},{"name":"NPC-02","genericName":"NPC-02","slug":"npc-02","indication":"Type 2 diabetes","status":"phase_3"},{"name":"NPC-07 for oral administration","genericName":"NPC-07 for oral administration","slug":"npc-07-for-oral-administration","indication":"Type 2 diabetes","status":"phase_3"},{"name":"NPC-15","genericName":"NPC-15","slug":"npc-15","indication":"Treatment of type 2 diabetes","status":"phase_3"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"neuroscience","drugs":[{"name":"NPC-12Y gel","genericName":"NPC-12Y gel","slug":"npc-12y-gel","indication":"Wound healing and tissue regeneration (specific indication under investigation in Phase 3)","status":"phase_3"},{"name":"Norethisterone,Ethinylestradiol","genericName":"Norethisterone,Ethinylestradiol","slug":"norethisterone-ethinylestradiol","indication":"Contraception","status":"phase_3"}]},{"name":"Neuroscience","slug":"neuroscience","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"infectious","drugs":[{"name":"NPC-16 Continuous Dosing Regimen Group","genericName":"NPC-16 Continuous Dosing Regimen Group","slug":"npc-16-continuous-dosing-regimen-group","indication":"Relapsing forms of multiple sclerosis","status":"phase_3"},{"name":"NPC-16 Standard Dosing Regimen Group","genericName":"NPC-16 Standard Dosing Regimen Group","slug":"npc-16-standard-dosing-regimen-group","indication":"Relapsing forms of multiple sclerosis","status":"phase_3"}]},{"name":"Infectious Disease","slug":"infectious-disease","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Sclerosol","genericName":"TALC","slug":"talc","indication":"Inoperable secondary intractable pneumothorax","status":"marketed"}]},{"name":"Cardiovascular","slug":"cardiovascular","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"cardiovascular","drugs":[{"name":"NPC-01","genericName":"NPC-01","slug":"npc-01","indication":"Type 2 diabetes","status":"phase_3"}]}],"pipeline":[{"name":"Sclerosol","genericName":"TALC","slug":"talc","phase":"marketed","mechanism":"Small molecule","indications":["Inoperable secondary intractable pneumothorax","Suppression of recurrence of malignant pleural effusions"],"catalyst":""},{"name":"IKH-01","genericName":"IKH-01","slug":"ikh-01","phase":"phase_3","mechanism":"IKH-01 is a small molecule that targets the SGLT2 receptor.","indications":["Type 2 diabetes"],"catalyst":""},{"name":"NPC-09","genericName":"NPC-09","slug":"npc-09","phase":"phase_3","mechanism":"NPC-09 is a small molecule that targets the SGLT2 receptor.","indications":["Type 2 diabetes"],"catalyst":""},{"name":"NPC-01","genericName":"NPC-01","slug":"npc-01","phase":"phase_3","mechanism":"NPC-01 is a small molecule that targets the SGLT2 receptor.","indications":["Type 2 diabetes","Heart failure"],"catalyst":""},{"name":"NPC-02","genericName":"NPC-02","slug":"npc-02","phase":"phase_3","mechanism":"NPC-02 is a small molecule that targets the SGLT2 receptor.","indications":["Type 2 diabetes"],"catalyst":""},{"name":"NPC-07 for oral administration","genericName":"NPC-07 for oral administration","slug":"npc-07-for-oral-administration","phase":"phase_3","mechanism":"NPC-07 is a small molecule that targets the SGLT2 receptor.","indications":["Type 2 diabetes"],"catalyst":""},{"name":"NPC-12Y gel","genericName":"NPC-12Y gel","slug":"npc-12y-gel","phase":"phase_3","mechanism":"NPC-12Y is a topical gel formulation designed to promote wound healing and tissue regeneration through growth factor delivery.","indications":["Wound healing and tissue regeneration (specific indication under investigation in Phase 3)"],"catalyst":""},{"name":"NPC-15","genericName":"NPC-15","slug":"npc-15","phase":"phase_3","mechanism":"NPC-15 is a small molecule that targets the SGLT2 receptor.","indications":["Treatment of type 2 diabetes"],"catalyst":""},{"name":"NPC-16 Continuous Dosing Regimen Group","genericName":"NPC-16 Continuous Dosing Regimen Group","slug":"npc-16-continuous-dosing-regimen-group","phase":"phase_3","mechanism":"NPC-16 is a small molecule that targets the sphingosine-1-phosphate receptor 1 (S1PR1) to modulate immune cell trafficking.","indications":["Relapsing forms of multiple sclerosis"],"catalyst":""},{"name":"NPC-16 Standard Dosing Regimen Group","genericName":"NPC-16 Standard Dosing Regimen Group","slug":"npc-16-standard-dosing-regimen-group","phase":"phase_3","mechanism":"NPC-16 is a small molecule that targets the sphingosine-1-phosphate receptor 1 (S1PR1) to modulate immune responses.","indications":["Relapsing forms of multiple sclerosis"],"catalyst":""},{"name":"Norethisterone,Ethinylestradiol","genericName":"Norethisterone,Ethinylestradiol","slug":"norethisterone-ethinylestradiol","phase":"phase_3","mechanism":"Norethisterone is a progestogen that acts as an agonist of the progesterone receptor, while ethinylestradiol is an estrogen that acts as an agonist of the estrogen receptor.","indications":["Contraception"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMivwFBVV95cUxQdW9iVFdYZTBVNUFwYVdId2tveDN4b0lWdkdyUGZudWlXV0VpMUZOVFg0dGE0dkozZVRyVmJ3RTdNdkJ0TXFmRGFicWV5Zjd3QVZmaGczVEsweGMtRGdOSWtjcXdPUm1BTHY3Q2lPWUlZVlRfRW5oek5kUXp0aTlpVnRSV1JPekhlMGw4VDJ4Y0lxRzRieVJmV09vZ25DZlBfQUxWV0lWOVVDU1N4bUtuLVJXWmxYY3JaLTF3aWdwWQ?oc=5","date":"2023-01-19","type":"pipeline","source":"Fierce Pharma","summary":"Nobelpharma America launches educational website to boost awareness for rare nerve disease - Fierce Pharma","headline":"Nobelpharma America launches educational website to boost awareness for rare nerve disease","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiswFBVV95cUxOWVBaWjlaWmxiOHY4V1lmNUNaWl84bWlqZjRBMWVUZ1pneW83ZTNtSEJZWDh2OFdxVEtJYk1WYk5odUZhTWdsb3g0ak1kLWhjOUx3LW52bWZPNDRieFktOVVMYlJTMlhrdmZTQUk5bnhNV1VvbFBRWTFwb2tLVkdVOC1oUnVkczNLMENnOVVqN2lBdTNRc3gzQl9ocnJnME9EN24zOHY0ZFpQRVQtcDNlbnEyQQ?oc=5","date":"2022-08-30","type":"pipeline","source":"NeurologyLive","summary":"Sirolimus Topical Gel Available for Facial Angiofibroma Associated With Tuberous Sclerosis Complex - NeurologyLive","headline":"Sirolimus Topical Gel Available for Facial Angiofibroma Associated With Tuberous Sclerosis Complex","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiswFBVV95cUxPMHg1blVTLW92RjUydGV6VzRjNktBOUFqYUwtYWZ4dWFoZkdRZDJQR1FxbzZFMG5ZUzMwejgxa1ZxMnZBZmwxOVViaVc0SkJ2TXRJUjU2anZWUU84SFZTeVJQeHpQRGh1MVFRTnNxMDBkWElXMEV3aGZLcXg4X1BzMElCLW52VWJwblFLOVNtY0NMcnZ0amRhd1dRTUlGbFN2QXpiQl9mRFdHSnhTdkVaVjlCYw?oc=5","date":"2022-08-29","type":"pipeline","source":"Managed Healthcare Executive","summary":"AllianceRx Walgreens Pharmacy, Total Care Rx Chosen to Distribute to Hyftor - Managed Healthcare Executive","headline":"AllianceRx Walgreens Pharmacy, Total Care Rx Chosen to Distribute to Hyftor","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi0wFBVV95cUxQN2FWTGtEdi0tQUp2ZG9tb0ZJWXBoaGE3cmpVWkF4aDVIMVNfYzNidzJ1ajU5UWNaSUpwX1JhYzVIOTNCOFFFZEdYSTlPSktUbmhZX0drNlNjOGU3R29ZRnYtQlM3Vi0tdS1oQlhLNnpTRWxqNHZWN3R1ZWZ6LUJ3b2xWTS1yNmNjMW9NMTVhbkhpa3JLa1FuajRrU2VpRl90T3B2ZmpFV2U4Zy01RjhKSG5sbFlXMnhtX2doWEN2RkpCeURzZ1RkeHczU2c4eVR1Y3c4?oc=5","date":"2022-07-25","type":"pipeline","source":"BioSpace","summary":"Nobelpharma America Debuts New Product, HYFTOR™ (sirolimus topical gel) 0.2%, at the 2022 World TSC Conference - BioSpace","headline":"Nobelpharma America Debuts New Product, HYFTOR™ (sirolimus topical gel) 0.2%, at the 2022 World TSC Conference","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimAFBVV95cUxQMGkyNHRReXdsb0xJQTBzSVE1S2xSWnJiUVdib293WE9vS3lSMm9BWDRxR2Y4eHd1OW9QaVhZMkxqQ0IwdjQ5X0MwVi1tUkktZGdJOXdwb08ybHhEWU9rN1FUdE1TV21nUEloY1FTV256NVRkRG5VSzBrcXRDeS1FSE5EeThNMU56dUpMbnJBUHhiSlZkV2pVMw?oc=5","date":"2022-04-05","type":"regulatory","source":"Fierce Pharma","summary":"In a first, FDA approves topical sirolimus for rare disease lesions - Fierce Pharma","headline":"In a first, FDA approves topical sirolimus for rare disease lesions","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMitAFBVV95cUxPSUs4amlWVGxVX0tidkhVdWxfemFNTXRpNzQzZjl5a0FXUGhKaUdoZnB3RzUyNnFwVG1nNjAzTk41cnkyOEdGcHY3Q056Q2x4WVI1aUltczlvaUNqN1doUEI1R1NMcXR0cTJ4Q3lJSjZ3M3FzRDcxdERfOGpmeWQ2T0EyZWpVa1JBUVhwNkRlb2piV285dXJwaDYtMGlrWWNpeTZWNlFsWVhnUDRaYTl1WEt1b2s?oc=5","date":"2022-04-04","type":"regulatory","source":"PR Newswire","summary":"FDA approves Nobelpharma's HYFTOR™ (sirolimus topical gel) 0.2% - PR Newswire","headline":"FDA approves Nobelpharma's HYFTOR™ (sirolimus topical gel) 0.2%","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTFBPYkNtcTU2MHUxMG0ya2FWaUlva2wyMWZqaUdFdENPckZtTldEWWlSNHlLMFRCNVJHc2c5X3BBNXJOV2NTN3BaNVNjQjNLeXRYY0JCeVU1dUc4dFZmQUk4?oc=5","date":"2021-11-03","type":"pipeline","source":"Nature","summary":"Small pharma takes a rare approach to treat neglected diseases - Nature","headline":"Small pharma takes a rare approach to treat neglected diseases","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi1AFBVV95cUxNX2pxXzA0MlhUSjE0SFZvZG1uczRDU0FjcU5mLTd2eXYwOEpiWGRnakhoZUFhSGJXZXNHdHRtR003VFRadnVrV2RrU2VybExpak5fWlhDM1U2clJ1NDlPbDNxMWRlczk5b2o1cEIxSHhoMlBCOV9jTXhTeWhlZDN0SjhXRlpTQ1lnZ2RPUVZaR0I3VUR5RlRZUUJQa0k4cXIwbWR3cDBSaTBXa09FRkZSbVZBNUszRHdRcEtrVTkzZll0QTR2UUd1OU1ySVBXVnU5ZDJWLQ?oc=5","date":"2021-06-22","type":"pipeline","source":"PR Newswire","summary":"Nobelpharma America Recognized by the TSC Alliance for Commitment to TSC Community - PR Newswire","headline":"Nobelpharma America Recognized by the TSC Alliance for Commitment to TSC Community","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinAFBVV95cUxQWTVPYUg5ajM0YUxQd1VHWUgyaFJzSTU1MWd3dlZONkU4R1BZOE5jaWRfWlpxMVhaVC1BQXZYdktzWHkyNW9yYVh5NkgtcFlfMUx2Xzg5dm1QNVdjS1laeHpxbWV3NTd6TnNKRTJ3RkNXR0RLWXJEWjVEYzB0YllOSHhLVVVpdklKODkyTlEyX0VBRkpfdU1hVXU4QWE?oc=5","date":"2020-09-01","type":"pipeline","source":"The Business Journals","summary":"Japanese biotech firm Nobelpharma expands to Montgomery County - The Business Journals","headline":"Japanese biotech firm Nobelpharma expands to Montgomery County","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiwFBVV95cUxQTFlmSFJTV0EtcDAxbVY3Wld6NmFwU1VUaXBVUHY4MWZHeTVWSjN2dVQyZ1ZIeTNhVGczYUhQb005eW05UHZvbzlZaWt3bUMyZ00tU3Jqc1NIbHFCaklxRElFMUFKUDNJbmc0S2hCQVRWX1RFOWRRenZObmRWQ2JwTzFvZk1KVUVmZkRN?oc=5","date":"2020-09-01","type":"earnings","source":"Montgomery Community Media","summary":"Japanese Company Opens American Headquarters In Bethesda - Montgomery Community Media","headline":"Japanese Company Opens American Headquarters In Bethesda","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilwFBVV95cUxONVdCeVhhSVgzRmdFMFhWeFBtRkxPZjhqVDh3cEFhalE3RzRKMnNYa3BpNlhLMVB1azBhTmJUMy1Oa0NwMTVZa25jTlNJWmJ5V0VNUlFZdWdlc2VvWGxJZGthSjhYQVRXMlRNOEJDUzU4QWJtdTU5TDN6alZtQnlnaTdtbmxOOXRMYk9RdE1EeV81bVJrYklF?oc=5","date":"2017-08-23","type":"trial","source":"Genetic Engineering and Biotechnology News","summary":"Ultragenyx Halts Ace-ER Development after Phase III Failure - Genetic Engineering and Biotechnology News","headline":"Ultragenyx Halts Ace-ER Development after Phase III Failure","sentiment":"negative"},{"url":"https://news.google.com/rss/articles/CBMingFBVV95cUxNQTg3TFgzcmQ4N3dHSFpndUNQNHNkNGozZGdpWEtNU2FFa1FoeTNXbXh1b1VtdUZXcG9xakZCWVAtNHN1VU1fU2dhTV81ekUwelgyOFFjU1B2NDg4Q0gzelNoOFlaNDhoWEJFZGlvQzhQNEQwc2lsLTZuQkwzTXFRcDF4WmRVbVd0OHlSeFlzdHo2elF5WWxKT2ZaZGJNdw?oc=5","date":"2017-01-31","type":"deal","source":"Fierce Biotech","summary":"Astellas buys rights to Auration's ruptured eardrum therapy - Fierce Biotech","headline":"Astellas buys rights to Auration's ruptured eardrum therapy","sentiment":"neutral"}],"patents":[],"drugCount":11,"phaseCounts":{"marketed":1,"phase_3":10},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}